Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus

NCT ID: NCT00513214

Last Updated: 2011-10-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 68 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2010-02-28

Brief Summary

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D).

The study is a dose-escalation study designed to evaluate route of administration (intravenous or subcutaneous), doses, and dosing regimens for future studies.

Conditions

Type 2 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

XOMA 052

Group Type: ACTIVE_COMPARATOR

XOMA 052

Intervention Type: DRUG

• Part 1, Single IV infusion at one of six dose levels (mg/kg).
• Part 2, Single SC injection at one of three dose levels (mg/kg).
• Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

• Part 1, Single IV infusion at one of six dose levels (mg/kg).
• Part 2, Single SC injection at one of three dose levels (mg/kg).
• Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).

Interventions

XOMA 052

• Part 1, Single IV infusion at one of six dose levels (mg/kg).
• Part 2, Single SC injection at one of three dose levels (mg/kg).
• Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).

Intervention Type: DRUG

Placebo

• Part 1, Single IV infusion at one of six dose levels (mg/kg).
• Part 2, Single SC injection at one of three dose levels (mg/kg).
• Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• American Diabetes Association (ADA) diagnostic criteria for T2D - Fasting blood glucose concentration ≥ 126 mg/dL (≥ 7.0 mmol/L) (must be measured within 35 days prior to Day 0) OR Symptoms of hyperglycemia (e.g., thirst, polyuria, weight loss, visual blurring) AND a casual/random plasma glucose value of ≥ 200 mg/dL (≥ 11.1 mmol/L) (must be measured within 35 days prior to Day 0)
• HbA1c ≥ 7.5% and ≤ 12% (DCCT standard)
• Current T2D of duration > 6 months at Screening
• T2D and other diseases must be stable. Stable disease is defined as disease that is judged stable by the investigator and which did not require a change in medications or dosing level on 4 or more consecutive days or 7 days in total within 35 days prior to Day 0.
• Age ≥ 18 and ≤ 70 at Screening
• Weight ≥ 80 lbs (36.3 kg) and ≤ 325 lbs (147.4 kg)
• BMI ≥ 23 and ≤ 40 kg/m2
• For female subjects of child-bearing age, a negative serum pregnancy test. For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study.
• Agree not to change diet and exercise regimen during the trial

Exclusion Criteria

• Use of the following medications - Anti-inflammatory therapy other than aspirin ≤ 100 mg/day; Immunosuppressive treatment; Beta 2 and non-selective adrenergic blockers (Note: selective beta 1 blockers are permitted); Thiazolidinediones; Glucagon-like peptide (GLP) agonists including DPP4 inhibitors
• Change in medication for diabetes within 35 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total
• Fasting C-peptide < 400 pM (< 1.20 μg/L)
• Hemoglobin < 8.0 g/dL, WBC < 3.0 X 103/mm3, platelet count < 125 X 103/mm3, creatinine > 1.5 mg/dL, AST/ALT > 2 X ULN, alkaline phosphatase > 2 X ULN
• Positive for GAD65 or IA-2 auto-antibodies
• Known HIV antibody, hepatitis B surface antigen, and/or hepatitis C antibody
• History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin
• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma
• Infectious disease - CRP > 30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening; History of recurrent infection or predisposition to infection; Active leg or foot ulcer
• Immunodeficiency
• Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding
• History or symptoms of a demyelinating disease
• Clinically significant diabetic macular edema and/or proliferative diabetic retinopathy by history or fundoscopy
• Receipt of a live (attenuated) vaccine within 3 months prior to Screening
• Major surgery within 35 days prior to Day 0
• Participation in an investigational drug or device trial within 30 days prior to Screening
• Use of a therapeutic monoclonal antibody within 90 days prior to Screening
• Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to the study drug

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

XOMA (US) LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pedro Urquilla, MD

Role: STUDY_DIRECTOR

XOMA (US) LLC

Locations

Escondido, California, United States

Miami Gardens, Florida, United States

Omaha, Nebraska, United States

San Antonio, Texas, United States

Countries

United States

Other Identifiers

X052073

Identifier Type: -

Identifier Source: org_study_id